Prevention of Prostate Cancer with Finasteride

US/European Perspective

Ian M. Thompson, Eric A. Klein, Scott M. Lippman, Charles A. Coltman, Bob Djavan

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Purpose: Prostate cancer is the most common male cancer, affecting one man in six. Prevention of this disease, even in a subset of patients would have a significant impact on public health. The results of the National Cancer Institute-sponsored Prostate Cancer Prevention Trial demonstrate that finasteride causes a substantial risk reduction across all known risk groups. We herein amplify on the results of this trial to assist patients and physicians in reaching individualized decisions. Materials and Methods: The results of the Prostate Cancer Prevention Trial were reviewed. Results: The PCPT demonstrated a 24.8% reduction in prostate cancer risk with the administration of finasteride. High-grade cancers were noted in 6.4% of finasteride patients compared to 5.1% of men receiving placebo. The increase in high-grade tumors was seen within one year of finasteride exposure and did not increase over time. This observation, combined with previous evidence demonstrating an alteration in cytologic and architectural features of prostate cancer with hormonal therapy suggests that the differences in high-grade disease may be an artifact and that application of Gleason grading to these tumors may not be appropriate. Discussion: Men should be presented the benefits and risks of taking finasteride and be assisted in integrating their sexual and urinary symptoms into their decision-making process. Blanket statements for or against the use of this medication ignore patient preferences and differential risk-benefit profiles from finasteride.

Original languageEnglish (US)
Pages (from-to)650-655
Number of pages6
JournalEuropean Urology
Volume44
Issue number6
DOIs
StatePublished - Dec 2003

Fingerprint

Finasteride
Prostatic Neoplasms
Neoplasms
National Cancer Institute (U.S.)
Patient Preference
Neoplasm Grading
Risk Reduction Behavior
Risk-Taking
Artifacts
Decision Making
Public Health
Placebos
Physicians

Keywords

  • Finasteride
  • Prevention
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Thompson, I. M., Klein, E. A., Lippman, S. M., Coltman, C. A., & Djavan, B. (2003). Prevention of Prostate Cancer with Finasteride: US/European Perspective. European Urology, 44(6), 650-655. https://doi.org/10.1016/j.eururo.2003.11.001

Prevention of Prostate Cancer with Finasteride : US/European Perspective. / Thompson, Ian M.; Klein, Eric A.; Lippman, Scott M.; Coltman, Charles A.; Djavan, Bob.

In: European Urology, Vol. 44, No. 6, 12.2003, p. 650-655.

Research output: Contribution to journalArticle

Thompson, IM, Klein, EA, Lippman, SM, Coltman, CA & Djavan, B 2003, 'Prevention of Prostate Cancer with Finasteride: US/European Perspective', European Urology, vol. 44, no. 6, pp. 650-655. https://doi.org/10.1016/j.eururo.2003.11.001
Thompson, Ian M. ; Klein, Eric A. ; Lippman, Scott M. ; Coltman, Charles A. ; Djavan, Bob. / Prevention of Prostate Cancer with Finasteride : US/European Perspective. In: European Urology. 2003 ; Vol. 44, No. 6. pp. 650-655.
@article{80001ffe061e456f92be392607a5246e,
title = "Prevention of Prostate Cancer with Finasteride: US/European Perspective",
abstract = "Purpose: Prostate cancer is the most common male cancer, affecting one man in six. Prevention of this disease, even in a subset of patients would have a significant impact on public health. The results of the National Cancer Institute-sponsored Prostate Cancer Prevention Trial demonstrate that finasteride causes a substantial risk reduction across all known risk groups. We herein amplify on the results of this trial to assist patients and physicians in reaching individualized decisions. Materials and Methods: The results of the Prostate Cancer Prevention Trial were reviewed. Results: The PCPT demonstrated a 24.8{\%} reduction in prostate cancer risk with the administration of finasteride. High-grade cancers were noted in 6.4{\%} of finasteride patients compared to 5.1{\%} of men receiving placebo. The increase in high-grade tumors was seen within one year of finasteride exposure and did not increase over time. This observation, combined with previous evidence demonstrating an alteration in cytologic and architectural features of prostate cancer with hormonal therapy suggests that the differences in high-grade disease may be an artifact and that application of Gleason grading to these tumors may not be appropriate. Discussion: Men should be presented the benefits and risks of taking finasteride and be assisted in integrating their sexual and urinary symptoms into their decision-making process. Blanket statements for or against the use of this medication ignore patient preferences and differential risk-benefit profiles from finasteride.",
keywords = "Finasteride, Prevention, Prostate cancer",
author = "Thompson, {Ian M.} and Klein, {Eric A.} and Lippman, {Scott M.} and Coltman, {Charles A.} and Bob Djavan",
year = "2003",
month = "12",
doi = "10.1016/j.eururo.2003.11.001",
language = "English (US)",
volume = "44",
pages = "650--655",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Prevention of Prostate Cancer with Finasteride

T2 - US/European Perspective

AU - Thompson, Ian M.

AU - Klein, Eric A.

AU - Lippman, Scott M.

AU - Coltman, Charles A.

AU - Djavan, Bob

PY - 2003/12

Y1 - 2003/12

N2 - Purpose: Prostate cancer is the most common male cancer, affecting one man in six. Prevention of this disease, even in a subset of patients would have a significant impact on public health. The results of the National Cancer Institute-sponsored Prostate Cancer Prevention Trial demonstrate that finasteride causes a substantial risk reduction across all known risk groups. We herein amplify on the results of this trial to assist patients and physicians in reaching individualized decisions. Materials and Methods: The results of the Prostate Cancer Prevention Trial were reviewed. Results: The PCPT demonstrated a 24.8% reduction in prostate cancer risk with the administration of finasteride. High-grade cancers were noted in 6.4% of finasteride patients compared to 5.1% of men receiving placebo. The increase in high-grade tumors was seen within one year of finasteride exposure and did not increase over time. This observation, combined with previous evidence demonstrating an alteration in cytologic and architectural features of prostate cancer with hormonal therapy suggests that the differences in high-grade disease may be an artifact and that application of Gleason grading to these tumors may not be appropriate. Discussion: Men should be presented the benefits and risks of taking finasteride and be assisted in integrating their sexual and urinary symptoms into their decision-making process. Blanket statements for or against the use of this medication ignore patient preferences and differential risk-benefit profiles from finasteride.

AB - Purpose: Prostate cancer is the most common male cancer, affecting one man in six. Prevention of this disease, even in a subset of patients would have a significant impact on public health. The results of the National Cancer Institute-sponsored Prostate Cancer Prevention Trial demonstrate that finasteride causes a substantial risk reduction across all known risk groups. We herein amplify on the results of this trial to assist patients and physicians in reaching individualized decisions. Materials and Methods: The results of the Prostate Cancer Prevention Trial were reviewed. Results: The PCPT demonstrated a 24.8% reduction in prostate cancer risk with the administration of finasteride. High-grade cancers were noted in 6.4% of finasteride patients compared to 5.1% of men receiving placebo. The increase in high-grade tumors was seen within one year of finasteride exposure and did not increase over time. This observation, combined with previous evidence demonstrating an alteration in cytologic and architectural features of prostate cancer with hormonal therapy suggests that the differences in high-grade disease may be an artifact and that application of Gleason grading to these tumors may not be appropriate. Discussion: Men should be presented the benefits and risks of taking finasteride and be assisted in integrating their sexual and urinary symptoms into their decision-making process. Blanket statements for or against the use of this medication ignore patient preferences and differential risk-benefit profiles from finasteride.

KW - Finasteride

KW - Prevention

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=0346905442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346905442&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2003.11.001

DO - 10.1016/j.eururo.2003.11.001

M3 - Article

VL - 44

SP - 650

EP - 655

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 6

ER -